These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9045352)

  • 1. [Development and characterization of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
    Ristol P; Gensana M; Fernández J; Massot M; Bhattacharya P; Jorquera JI
    Sangre (Barc); 1996 Apr; 41(2):125-30. PubMed ID: 9045352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
    Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
    Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system.
    Burnouf T; Goubran HA; Radosevich M; Sayed MA; Gorgy G; El-Ekiaby M
    Vox Sang; 2006 Jul; 91(1):56-62. PubMed ID: 16756602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Study of a therapeutic concentrate of factor VIII/vWf prepared in a closed system].
    Mazurier C; Maillard J; Parquet-Gernez A; Goudemand M
    Rev Fr Transfus Immunohematol; 1982 Feb; 25(1):25-43. PubMed ID: 6803339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virus inactivation in a factor VIII/VWF concentrate treated using a solvent/detergent procedure based on polysorbate 20.
    Roberts PL; Lloyd D; Marshall PJ
    Biologicals; 2009 Jan; 37(1):26-31. PubMed ID: 18848782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation of intermediate-purity factor VIII concentrate by direct gel filtration of cryoprecipitate.
    Teh LC
    Vox Sang; 1993; 65(4):251-7. PubMed ID: 8310677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromatographic preparation of a therapeutic highly purified von Willebrand factor concentrate from human cryoprecipitate.
    Burnouf-Radosevich M; Burnouf T
    Vox Sang; 1992; 62(1):1-11. PubMed ID: 1580062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A highly purified factor VIII:c concentrate prepared from cryoprecipitate by ion-exchange chromatography.
    Burnouf T; Burnouf-Radosevich M; Huart JJ; Goudemand M
    Vox Sang; 1991; 60(1):8-15. PubMed ID: 1905084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A solvent/detergent-treated and 15-nm filtered factor VIII: a new safety standard for plasma-derived coagulation factor concentrates.
    Chtourou S; Porte P; Nogré M; Bihoreau N; Cheesman E; Samor B; Sauger A; Raut S; Mazurier C
    Vox Sang; 2007 May; 92(4):327-37. PubMed ID: 17456157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative multi-laboratory assessment of three factor VIII/von Willebrand factor concentrates.
    Favaloro EJ; Bukuya M; Martinelli T; Tzouroutis J; Duncan E; Welldon K; Collecutt M; Aumann H; Thom J; Gilmore G
    Thromb Haemost; 2002 Mar; 87(3):466-76. PubMed ID: 11916080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Functionality of von Willebrand factor present in Fanhdi: adhesion to the vascular subendothelium in vitro].
    Escolar G; Viñas M; Pino M; Casamiquela R; Jorquera JI
    Sangre (Barc); 1997 Oct; 42(5):377-81. PubMed ID: 9424737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a heat-treated factor VIII/von Willebrand factor concentrate prepared from heparinized plasma.
    Palmer DS; Ganz PR; Perkins H; Rosborough D; Rock G
    Thromb Haemost; 1990 Jun; 63(3):392-402. PubMed ID: 2119525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
    Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
    Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. von Willebrand factor contained in a high purity FVIII concentrate (Fanhdi) binds to platelet glycoproteins and supports platelet adhesion to subendothelium under flow conditions.
    Rivera J; Escolar G; Casamiquela R; Bravo MI; Jorquera JI; Castillo R; Ordinas A; Vicente V
    Haematologica; 1999 Jan; 84(1):5-11. PubMed ID: 10091386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro study of a triple-secured von Willebrand factor concentrate.
    Mazurier C; Poulle M; Samor B; Hilbert L; Chtourou S
    Vox Sang; 2004 Feb; 86(2):100-4. PubMed ID: 15023178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VWF/FVIII complex and the management of patient with inhibitors: from laboratory to clinical practice.
    Berntorp E
    Haemophilia; 2007 Dec; 13 Suppl 5():69-72. PubMed ID: 18078401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro studies, pharmacokinetic studies and clinical use of a high purity double virus inactivated FVIII/VWF concentrate (Immunate) in the treatment of von Willebrand disease.
    Ver Elst KM; van Vliet HD; Kappers-Klunne MC; Leebeek FW
    Thromb Haemost; 2004 Jul; 92(1):67-74. PubMed ID: 15213847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Properties of a concentrated minipool solvent-detergent treated cryoprecipitate processed in single-use bag systems.
    Burnouf T; Caron C; Radosevich M; Goubran HA; Goudemand J; El-Ekiaby M
    Haemophilia; 2008 Sep; 14(5):956-62. PubMed ID: 18565126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severely heated therapeutic factor VIII concentrate of high specific activity.
    Winkelman L; Owen NE; Evans DR; Evans H; Haddon ME; Smith JK; Prince PJ; Williams JD; Lane RS
    Vox Sang; 1989; 57(2):97-103. PubMed ID: 2506696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterisation of a novel high-purity, double virus inactivated von Willebrand Factor and Factor VIII concentrate (Wilate).
    Stadler M; Gruber G; Kannicht C; Biesert L; Radomski KU; Suhartono H; Pock K; Neisser-Svae A; Weinberger J; Römisch J; Svae TE
    Biologicals; 2006 Dec; 34(4):281-8. PubMed ID: 16500114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.